There are thousands of different strains of Cannabis Sativa, each with its own unique profile of cannabinoids, and terpenes and other components. Finding the best strain to use for a particular disease is a key research theme.
Our longstanding association with the Australian hemp growing company Ecofibre has allowed the Lambert Initiative privileged access to a variety of hemp plant materials and extracts for use in our research. Of particular note is the vast seed bank owned by Ecofibre with more than 200 different strains of Cannabis Sativa, each with its own unique profile of cannabinoids and terpenes. This is currently curated by Professor Graham King and colleagues at Southern Cross University.
Ultimately, it may be that specific strains of cannabis are particularly well suited to treat particular diseases. Finding the best strain to use for a particular disease is a key research theme. For example, the Ecofibre strain called CHY is enriched with the cannabinoid tetrahydrocannabivarin (THCV). This cannabinoid may help to combat obesity and diabetes.
The hemp extracts that we obtain from Ecofibre are sometimes used in our research without further refinement, allowing the effects of full spectrum hemp extracts to be determined in our cellular and animal models, and in future clinical trials. At other times we use the technique of Flash Chromatography to separate and purify individual cannabinoids from extracts.
In all our ongoing preclinical research, we aim to examine whether full spectrum extracts are more efficacious than individual cannabinoids in treating disease. The supposed superiority of whole plant extracts is sometimes referred to as the ‘entourage effect’.
NSW Health Licenses obtained – February 2016
Extraction commenced – November 2016
The project is ongoing
Plant genetics and chemistry
The Lambert Initiative
We have successfully extracted tetrahydrocannabivarin (THCV), cannabidiolic acid (CBDA) and tetrahydrocannabinolic acid (THCA) from Ecofibre CHY strain